Genfit SA (GNFT)
3.79
0.00 (0.00%)
USD |
NASDAQ |
May 16, 16:00
3.79
0.00 (0.00%)
After-Hours: 20:00
Genfit Shareholders Equity (Quarterly): 75.11M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 75.11M |
| June 30, 2023 | 80.98M |
| December 31, 2022 | 101.37M |
| June 30, 2022 | 114.03M |
| December 31, 2021 | 134.84M |
| June 30, 2021 | 38.75M |
| December 31, 2020 | -20.21M |
| June 30, 2020 | 35.29M |
| December 31, 2019 | 94.17M |
| June 30, 2019 | 109.20M |
| December 31, 2018 | 23.95M |
| June 30, 2018 | 80.93M |
| June 30, 2018 | 80.93M |
| December 31, 2017 | 121.72M |
| June 30, 2017 | 137.61M |
| June 30, 2017 | 137.61M |
| December 31, 2016 | 150.96M |
| June 30, 2016 | 100.92M |
| June 30, 2016 | 100.92M |
| Date | Value |
|---|---|
| December 31, 2015 | 60.59M |
| June 30, 2015 | 71.29M |
| June 30, 2015 | 71.29M |
| December 31, 2014 | 85.64M |
| June 30, 2014 | 77.97M |
| June 30, 2014 | 77.97M |
| December 31, 2013 | 19.46M |
| June 30, 2013 | 24.04M |
| June 30, 2013 | 24.04M |
| December 31, 2012 | 9.038M |
| June 30, 2012 | 3.249M |
| June 30, 2012 | 3.249M |
| December 31, 2011 | 5.773M |
| June 30, 2011 | 5.044M |
| June 30, 2011 | 5.044M |
| December 31, 2010 | 11.16M |
| June 30, 2010 | 15.20M |
| December 31, 2009 | 22.19M |
| June 30, 2009 | 27.06M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-20.21M
Minimum
Dec 2020
134.84M
Maximum
Dec 2021
76.36M
Average
87.58M
Median
Shareholders Equity (Quarterly) Benchmarks
| Cellectis SA | 84.70M |
| Biophytis SA | -4.264M |
| DBV Technologies SA | 111.65M |
| Adaptimmune Therapeutics PLC | 39.51M |
| Akari Therapeutics PLC | -0.229M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 192.20M |
| Total Liabilities (Quarterly) | 117.09M |
| Debt to Equity Ratio | 0.9462 |
| Current Ratio | 2.940 |
| Net Debt Paydown Yield | -6.06% |